Stay updated with breaking news from James paul scopa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Canaccord Genuity Group assumed coverage on shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) in a research note released on Monday morning, Briefing.com reports. The brokerage issued a buy rating and a $71.00 price objective on the stock. Several other analysts have also recently commented on DICE. HC Wainwright restated a buy rating and issued […] ....
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 8,130,000 shares, a growth of 18.7% from the March 15th total of 6,850,000 shares. Based on an average daily trading volume, of 483,200 shares, the days-to-cover ratio is presently 16.8 […] ....
Needham & Company LLC assumed coverage on shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) in a research report sent to investors on Friday, MarketBeat reports. The brokerage issued a buy rating and a $56.00 target price on the stock. DICE has been the topic of several other research reports. HC Wainwright reissued a buy […] ....
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 6,850,000 shares, an increase of 13.2% from the February 28th total of 6,050,000 shares. Currently, 17.8% of the shares of the stock are sold short. Based on […] ....
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 6,850,000 shares, a growth of 13.2% from the February 28th total of 6,050,000 shares. Currently, 17.8% of the shares of the company are sold […] ....